MiMedx Group (NASDAQ:MDXG) Earns “Overweight” Rating from Cantor Fitzgerald

MiMedx Group (NASDAQ:MDXG)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a report issued on Thursday,Benzinga reports. They presently have a $13.00 price objective on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 58.21% from the stock’s previous close.

Separately, StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, MiMedx Group presently has an average rating of “Buy” and a consensus target price of $12.40.

MiMedx Group Stock Performance

Shares of MDXG stock traded up $0.21 during mid-day trading on Thursday, reaching $8.22. 211,544 shares of the company’s stock traded hands, compared to its average volume of 554,180. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The firm has a market capitalization of $1.21 billion, a PE ratio of 14.98 and a beta of 1.94. MiMedx Group has a 12 month low of $5.47 and a 12 month high of $10.14. The firm has a 50 day moving average price of $8.75 and a two-hundred day moving average price of $7.68.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $92.91 million during the quarter, compared to analysts’ expectations of $89.42 million. On average, research analysts forecast that MiMedx Group will post 0.3 EPS for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors have recently added to or reduced their stakes in MDXG. Invesco Ltd. boosted its position in shares of MiMedx Group by 2.2% during the fourth quarter. Invesco Ltd. now owns 56,565 shares of the company’s stock worth $544,000 after acquiring an additional 1,226 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of MiMedx Group by 1.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 183,021 shares of the company’s stock valued at $1,082,000 after purchasing an additional 1,822 shares in the last quarter. Disciplined Growth Investors Inc. MN grew its position in shares of MiMedx Group by 0.8% during the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock valued at $2,100,000 after purchasing an additional 2,737 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of MiMedx Group by 77.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company’s stock worth $63,000 after purchasing an additional 2,837 shares during the last quarter. Finally, IMG Wealth Management Inc. purchased a new position in MiMedx Group during the 4th quarter valued at approximately $28,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.